Mesoblast Hires Regeneron Veteran to Drive FDA-Approved Ryoncil Into New Markets

Mesoblast strengthens leadership with clinical development and medical affairs appointment

Mesoblast Limited (ASX: MSB) has announced the appointment of Teresa Montagut MD, PhD as Head of Clinical Development and Medical Affairs, a newly established position reporting to Chief Medical Officer Dr. Eric Rose. The appointment signals a strategic push to expand the company’s FDA-approved product Ryoncil into new indications across paediatric and adult inflammatory conditions.

Dr. Montagut will lead Mesoblast’s medical affairs organisation, focusing on clinical collaborations, investigator-initiated trials, and engagement with healthcare professionals and key opinion leaders. The role represents a growth-stage hire designed to accelerate clinical expansion rather than maintain existing operations.

What Dr. Montagut brings to Mesoblast

Dr. Montagut joins from Regeneron, where she most recently served as Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs for Investigator Sponsored Studies in gastrointestinal and genitourinary areas. Her career track record demonstrates direct expertise in cancer immunotherapy and investigator-led clinical programmes across multiple major pharmaceutical companies.

Career credentials and qualifications:

• Previous employers: Novartis, Genentech, Atara Biotherapeutics
• Education: MD from Universidad Nacional Autónoma de México
• Advanced degree: PhD in Tumor Immunology from Memorial Sloan Kettering Cancer Center/Cornell University
• Fellowships: Massachusetts General Hospital, Howard Hughes Medical Institute, Rockefeller University
• Board service: Director, Global Pediatric Alliance (maternal and paediatric healthcare in under-served indigenous communities in Latin America, particularly Mexico)

Her background in translating clinical science into patient outcomes, particularly through investigator-sponsored studies, aligns with Mesoblast’s stated expansion strategy for Ryoncil. The appointment brings proven expertise in executing the precise clinical development pathway the company aims to pursue.

What is an investigator-initiated trial?

Investigator-initiated trials (IITs) are clinical studies proposed and led by independent researchers rather than the pharmaceutical company itself. This trial structure allows companies to generate real-world evidence across broader patient populations without bearing the full financial burden of company-sponsored development programmes.

IITs serve as a capital-efficient pathway to support label expansions into new indications. They build relationships with key opinion leaders who influence prescribing decisions and treatment guidelines. For a biotech with an already FDA-approved therapy, IITs can accelerate market penetration by demonstrating efficacy in patient populations beyond the original approval.

Dr. Montagut’s specific expertise in managing investigator-sponsored studies at Regeneron directly supports this commercial strategy, offering Mesoblast an established playbook for expanding Ryoncil’s approved uses.

Strategic priorities for the new role

The announcement outlined six core responsibilities for the newly created position, each designed to expand Mesoblast’s clinical and commercial footprint:

1. Lead medical affairs organisation
2. Foster clinical collaborations with healthcare professionals
3. Spearhead investigator-initiated trials
4. Enhance clinical and medical communications
5. Engage with key opinion leaders
6. Support development of cell therapy programmes in paediatric and adult inflammatory conditions

The role is outward-facing, focused on building relationships with prescribers and researchers who will expand Ryoncil’s clinical applications. This positioning indicates a market penetration strategy rather than purely internal research and development.

CEO perspective

Dr. Silviu Itescu, Chief Executive Officer

“Teri’s commitment to scientific excellence and her expertise in investigator-initiated clinical trial execution is central to successful implementation of our strategy to expand the range of indications of our FDA approved product Ryoncil in pediatric and adult inflammatory conditions, as well as advancing our pipeline of transformative cellular therapies.”

Mesoblast’s pipeline and commercial context

Ryoncil represents the first FDA-approved mesenchymal stromal cell (MSC) therapy, approved for steroid-refractory acute graft versus host disease (SR-aGvHD) in paediatric patients 2 months and older. The company is now developing Ryoncil for SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, while advancing rexlemestrocel-L for heart failure and chronic low back pain.

Mesoblast has established commercial partnerships in Japan, Europe, and China, supported by an intellectual property portfolio of over 1,000 granted patents or patent applications. These patents provide commercial protection extending through at least 2044 across major markets.

The appointment positions Mesoblast to convert its existing FDA approval into expanded revenue streams through new indications and broader prescriber adoption. Dr. Montagut’s role centers on building the medical affairs infrastructure required to support potential label expansions.

What this means for investors

The Teresa Montagut appointment represents a leadership investment that signals confidence in near-term pipeline expansion. Her investigator-initiated trial expertise accelerates capital-efficient indication expansion, whilst the newly created medical affairs capability builds commercial infrastructure ahead of potential Ryoncil label expansions. The hire reflects a growth-stage strategy for a company with regulatory approval already secured.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors getting FREE breaking ASX healthcare and biotech news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment market-moving announcements break.